aid: entactbio
name: Entact Bio
description: 'Entact Bio is a preclinical-stage biotechnology company based in Watertown,
  Massachusetts, developing a new class of small-molecule precision medicines called
  Enhancement-Targeting Chimeric (ENTAC) molecules. Where targeted protein degradation
  removes disease-causing proteins, Entact Bio works in the opposite direction: its
  ENTAC molecules recruit deubiquitinases (DUBs) to strip ubiquitin chains from beneficial
  proteins in order to extend their half-life, relocate them, or otherwise restore
  their function. The company''s proprietary Encompass platform combines biological,
  chemical, and computational tools to identify disease targets amenable to protein
  enhancement across oncology, autoimmune disease, and rare genetic disorders. Entact
  Bio launched in December 2022 with an $81 million Series A co-led by Qiming Venture
  Partners USA and venBio Partners, with participation from Abingworth, Brandon Capital,
  and others. It is a therapeutics research organization and publishes no public developer
  program, API, or machine-readable API artifacts.'
url: https://raw.githubusercontent.com/api-evangelist/entactbio/refs/heads/main/apis.yml
x-type: company
x-source: harvest:secondary-market
x-tier: stub
x-tier-reason: harvest
specificationVersion: '0.23'
created: '2026-08-12'
modified: '2026-08-12'
tags:
- Company
- Biotechnology
- Pharmaceuticals
- Drug Discovery
- Life Sciences
- Targeted Protein Degradation
- Preclinical
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: DomainSecurity
  url: security/entactbio-domain-security.yml
- type: Website
  url: https://entactbio.com/
- type: About
  url: https://entactbio.com/science/
- type: Team
  url: https://entactbio.com/team/
- type: News
  url: https://entactbio.com/news-publications/
- type: Careers
  url: https://entactbio.com/careers/
- type: Contact
  url: https://entactbio.com/contact-us/
- type: LinkedIn
  url: https://www.linkedin.com/company/entact-bio
- type: Crunchbase
  url: https://www.crunchbase.com/organization/entact-bio
- type: LLMsTxt
  url: llms/entactbio-llms.txt
x-enrichment:
  date: '2026-08-12'
  status: minimal
  artifacts_added: 4
  pass: local-v1
x-coverage:
  state: blocked
  reason: bot-challenge
  detail: >-
    entactbio.com is fronted by a SiteGround bot-protection edge that answers every
    path — including the site root and /robots.txt — with HTTP 202, an
    `sg-captcha: challenge` header and a 180-byte meta-refresh shell pointing at
    /.well-known/sgcaptcha/, so not one page, spec path or /.well-known/ document
    could be read from the provider's own host under any user agent; DNS separately
    shows no api./docs./developer./portal. host to retry against, and the company is
    a preclinical therapeutics business with no evident developer program.
  evidence:
  - url: https://entactbio.com/
    status: 202
  - url: https://entactbio.com/robots.txt
    status: 202
  - url: https://entactbio.com/llms.txt
    status: 202
  - url: https://entactbio.com/openapi.json
    status: 202
  - url: https://entactbio.com/.well-known/agent-card.json
    status: 202
  - url: https://entactbio.com/.well-known/security.txt
    status: 202
  - url: https://api.github.com/orgs/EntactBio
    status: 200
  checked: '2026-08-12'